Search

This study was conducted using a nationwide health care database of Japan between 1 April 2008 and 30 September 2022 to evaluate the economic burden on patients with mantle cell lymphoma (MCL). Structural equation modeling (SEM) is an advanced multivariate analysis framework used to assess the relationships between observed and latent variables within predefined causal models. In this study, SEM was employed to identify cost drivers and estimate variables related to MCL treatment cost. A total of 2,838 patients having at least one confirmed diagnosis of MCL participated in this study. As for the index regimen, a combination of bendamustine rituximab was the most frequently used (n = 328), followed by rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone-like regimen (n = 112), and others. The median of total health care cost (unadjusted and adjusted) were 32,228 USD and 31,918 USD, respectively. The mean (SD) of the frequency of bleeding treatment was 23 (35) per year, and that of outpatient visits was 19 (12) per year. SEM analysis revealed Bruton tyrosine kinase inhibitor-based treatment as a cost driver (β: 0.398 [0.340; 0.457], p < 0.001). Key health care resource utilization (HCRU) factors associated with an increased cost were the total length of hospitalization (β: 0.598 [0.551; 0.646], p < 0.001) and number of outpatient visits (β: 0.132 [0.083; 0.180], p < 0.001). This real-world study delivers insights for optimizing MCL care in Japan. [ABSTRACT FROM AUTHOR]

Background: Type-1 diabetes mellitus (T1DM) is one of the most widespread chronic endocrine diseases among children and adolescents globally. Many barriers contribute to the challenge of adherence to treatment regimens among adolescents with T1DM. Purpose: This study explores the barriers that influence adherence to treatment regimens among adolescents with T1DM. Methods: Cross-sectional, descriptive, and exploratory designs were utilized. Convenience sampling was used to recruit 76 adolescents with T1DM from three hospitals in Jordan who were asked to complete the T1DM Parents' and Adolescents' Knowledge Questionnaire-related barriers section (T1DM-PAKQ). Results: Multiple regression revealed that six out of 12 factors significantly explained about 32% of the model. Barriers that significantly affect adherence to the treatment regimens among adolescents with T1DM include: psychological support (ß= 0.998, t= 21.218, p<0.001), the cost of reaching the hospital (ß= 0.961, t= 13.810, p <0.001), time available to communicate with the physician (ß = 0.981, t= 16.524, p <0.001), overcrowding of the outpatient clinic (ß = 0.921, t= 11.269, p <0.001), the hospital is far from home (ß = 0.885, t= 10.221, p <0.001), sick leave from my school or workplace (ß = 0.880, t= 9.939, p <0.001). Conclusion: For individuals with T1DM, adherence to a treatment regimen is crucial for managing the condition effectively and maintaining overall health. The findings from the present study suggest that adolescents' adherence to treatment regimens is influenced by barriers that could be managed. Implications for Nursing: Nurses in different positions should support adolescents with T1DM and assist them in adherence to treatment regimens. [ABSTRACT FROM AUTHOR]

Due to the growing threat of antimicrobial resistance, the search and development of new drugs to treat infectious mammary gland diseases of high yielding cows is an urgent task. The paper presents data on the microbiota composition of milk from high yielding cows suffering from subclinical mastitis; 144 microbial isolates were recovered from 70 milk samples; with the highest number of Staphylococcus aureus and Streptococcus dysgalactiae detected (22.2 and 16.0%, respectively). The study showed that a significant number of Staphylococcus aureus isolates (53.1%) were resistant to I generation cephalosporins; 52.6% of the isolated Streptococcus dysgalactiae strains showed resistance to tetracyclines; 33.3% of Staphylococcus haemolyticus isolates were resistant to macrolides. 42.1; 35.3 and 62.5% of Enterococcus faecium, Aerococcus viridans and coliform bacteria isolates, respectively, were resistant to penicillins. 38.5% of Staphylococcus epidermidis isolates were found to be resistant to tetracyclines. Corynebacterium pseudotuberculosis isolates showed equal resistance to penicillin and tetracycline antimicrobials (20.0%). The research revealed presence of multi-drug resistant coliform bacteria, Streptococcus dysgalactiae, Aerococcus viridans, Staphylococcus aureus strains. Experiments to study the effect of the new nisin-based pharmaceutical formulation on microbiota of milk from cows with subclinical mastitis were carried out using 35 high yielding cows. A microbiological testing of cow milk on day 14 from the beginning of the treatment showed that the number of microbiota-free samples increased to 88.6%, while in 1.4% of cases Staphylococcus aureus isolates were recovered (103 CFU/mL). The titers of coliform and Staphylococcus aureus bacteria isolated in 1.4% (101 CFU/mL) and 2.7% (102 CFU/mL) of cases, respectively, were not etiologically significant.

Purpose Methods Results Conclusions To investigate if the initial treatment response can predict the 1‐year treatment outcomes in patients with neovascular age‐related macular degeneration (nAMD) treated according to the observe‐and‐plan (O&P) regimen.In this prospective cohort study, treatment‐naïve patients with nAMD were enrolled consecutively and followed for 1 year while being treated according to the O&P regimen. The treatment response was determined initially post‐loading doses and after 1 year. The functional treatment response (fTR) was determined by the change in best corrected visual acuity, while the morphological treatment response (mTR) was assessed by central retinal thickness and the presence of sub‐ and intraretinal fluid on optical coherence tomography and categorized as good, partial, and poor responders. The relative risk (RR) of the initial treatment response for predicting 1‐year treatment response was assessed.One hundred patients were included and 94 completed the 1‐year follow‐up. Patients with an initial good fTR and initial poor fTR had an RR of 4.1 (95% CI 1.8–9.2) and 4.3 (95% CI 2.2–8.3), respectively, of remaining in the same response category at 1 year. Similarly, patients with an initial good mTR and initial poor mTR had an RR of 3.0 (95% CI 1.8–4.8) and 8.7 (95% CI 3.0–25.1), respectively, of remaining in the same response category at 1 year.Both the anatomic and visual functional response after 3 loading doses are predictive of the anatomic and functional outcomes at 1 year in patients with nAMD treated according to the O&P regimen. [ABSTRACT FROM AUTHOR]

Purpose: The Observe‐and‐Plan (O&P) regimen allows for individualised treatment. In this study, we evaluated injection burden and intervals using aflibercept in an O&P regimen for eyes with neovascular age‐related macular degeneration (AMD). Methods: This was a retrospective registry‐based study of treatment‐naïve eyes with neovascular AMD. Treatment data were compiled for 3 years after commencement of intravitreal aflibercept therapy. We evaluated clinical consequences at the first follow‐up after loading dose, the proportion of patients who obtained and kept dry macula after loading dose, number of injections and intervals between injections. Results: Data were obtained for 1103 eyes. After loading dose, 0.4% were lost to follow‐up, 7.5% discontinued, 50.9% booked for further injections and 41.3% booked for monthly observations. After loading dose, the macula remained dry in 49.2% at 3 months, 34.0% at 6 months, 23.7% at 12 months and 15.2% at 24 months. For the entire population, median cumulative total number of injections was 7, 12 and 15, after 1, 2 and 3 years, respectively. After the 3rd year, the proportion of eyes in the short 4–6 weeks treatment interval was 51.1%, 8 weeks interval was kept in 14.4% and the extended treatment intervals of 10 and 12 weeks was possible in 34.4%. Conclusion: After loading dose, one in two eyes required further injections. A large proportion required therapy with shorter intervals than the label‐recommended 8 weeks. The large majority of those who obtained a dry macula after loading dose turned exudative again, mostly within the first 3 months. [ABSTRACT FROM AUTHOR]

Introduction: The treatment landscape for type 2 diabetes mellitus (T2DM) is complex and constantly evolving, and real-world evidence of prescribing patterns is limited. The objectives of this study were to characterize lines of therapy (LOTs), calculate the length of time spent on each LOT, and identify the reasons for the LOT end among patients who initiated oral semaglutide for T2DM. Methods: This retrospective, claims-based study included commercial and Medicare Advantage adults with T2DM. Data from November 1, 2019, and June 30, 2020, were obtained from Optum Research Database. Patients with ≥ 1 claim for oral semaglutide and continuous health plan enrollment for ≥ 12 months prior to (baseline period) and ≥ 6 months following (follow-up period) the date of the first oral semaglutide claim were included. LOT 1 began on the date of the first oral semaglutide claim. The start date of any subsequent LOTs was the date of the first claim for an additional non-insulin anti-diabetic drug class or a reduction in drug class with use of commitment medications. The LOT ended at the first instance of medication class discontinuation, change in regimen or end of follow-up. Results: Of the 1937 patients who initiated oral semaglutide, 950 (49.0%) remained on their initial regimen over the 6-month follow-up period, 844 (43.6%) had at least one subsequent LOT, and 89 (4.6%) had at least two subsequent LOTs. Among patients with more than one LOT, approximately 20%–25% used oral semaglutide as monotherapy or combination therapy during LOTs 2 and 3. Metformin was frequently used during treatment across all LOTs. Conclusion: This study provides insight for physicians and payers into the real-world prescribing practices within the first 6 months following oral semaglutide initiation and fills the gap in understanding the frequency of regimen changes in the constantly evolving and complex environment of T2DM care. Plain Language Summary: Type 2 diabetes mellitus is a disease which, over time, can cause higher than normal levels of sugar in the blood (hyperglycemia) which can be harmful if not treated. Treatment for type 2 diabetes mellitus can be complex, and how doctors prescribe medications is always changing. For some people with type 2 diabetes mellitus who are overweight or obese, it is recommended for patients to use certain medications that can help with weight management such as semaglutide and metformin. This study aims to fill gaps in current treatment knowledge about type 2 diabetes mellitus patients and their treatment of oral semaglutide. Researchers in this study explored how patients treated with oral semaglutide differentiated among line of therapies, how long patients stuck to them and why they stopped. The study found that those patients who started with oral semaglutide, almost half of those patients stuck to their initial treatment plan for the entire 6 months. When it came to the top ten treatment plans, about 20% of patients used oral semaglutide alone and about 25% of patients used oral semaglutide plus an additional treatment option. Metformin was frequently used during treatment across all line of therapies. There is little information on the real-life setting of treatment after the start of therapy for type 2 diabetes mellitus. The results from this study show what happens when patients start using oral semaglutide and helps healthcare providers understand how often treatment plans can change in type 2 diabetes mellitus care. [ABSTRACT FROM AUTHOR]

Copyright of Die Unfallchirurgie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Amygdalin is purported to exhibit anti-cancer properties when hydrolyzed to hydrogen cyanide (HCN). However, knowledge about amygdalin efficacy is limited. A questionnaire evaluating the efficacy, treatment, and dosing protocols, reasons for use, HCN levels, and toxicity was distributed to physicians and healers in Germany, providing amygdalin as an anti-cancer drug. Physicians (20) and healers (18) provided amygdalin over 8 (average) years to nearly 80 annually treated patients/providers. Information about amygdalin was predominantly obtained from colleagues (55%). Amygdalin was administered both intravenously (100%) and orally (32%). Intravenous application was considered to maximally delay disease progression (90%) and relieve symptoms (55%). Dosing was based on recommendations from colleagues (71%) or personal experience (47%). If limited success became apparent after an initial 3g/infusion, infusions were increased to 27g/infusion. Treatment response was primarily monitored with established (26%) and non-established tumor markers (19%). 90% did not monitor HCN levels. Negative effects were restricted to a few dizzy spells and nausea. Only 58% were willing to participate in clinical trials or contribute data for analysis (34%). Amygdalin infusions are commonly administered by healers and physicians with few side effects. The absence of standardized treatment calls for guidelines. Since intravenous application bypasses metabolization, re-evaluation of its mode of action is required. [ABSTRACT FROM AUTHOR]

IntroductionProliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a chronic glomerular disease caused by monoclonal gammopathy. IgG (mainly IgG3) is the most commonly involved isotype of PGNMID. Here we illustrated a novel medication regimen for the rare variant of PGNMID with deposition of monoclonal immunoglobulin light chain only (PGNMID-LC). Daratumumab has been proved effective in the treatment of plasma cell myeloma while its effect for PGNMID-LC has rarely been reported.MethodsA daratumumab combination therapy (D-VCd regimen, specifically are daratumumab + dexamethasone + bortezomib + cyclophosphamide) was adopted to treat a patient diagnosed with PGNMID-LC.ResultsThe utility of D-VCd regimen showed a favorable effect in this patient. After the fixed course, his clinical symptom, laboratory parameters, neoplastic plasma cells clonity all restored to normal range, and no obvious disease progression was observed throughout the treatment. After a follow up of 14 months, no significant renal or hematological disease progression has been observed.ConclusionThis case underscores the utility of D-VCd regimen in treatment of PGNMID-LC, and it’s inferred that daratumumab regimen has clinical effects in the disease primarily through targeting tumor clonity. However, data on the use of daratumumab (either in monotherapy or in combination) in clinical trials of PGNMID-LC is currently so limited that that more experiments are needed to support the inference.

Aim. To study the effect of various therapy regimens with enhanced external counterpulsation (EECP) on exercise tolerance, quality of life, indices of structural and functional state of cardiovascular system in patients with stable coronary artery disease (CAD) complicated by chronic heart failure (CHF).Material and methods. The study included patients with stable CAD complicated by CHF with reduced and intermediate left ventricular ejection fraction (LVEF) from the randomized EXCEL trial (NCT05913778; n=120) and additionally patients with similar inclusion and exclusion criteria (n=90) who were randomized into groups with different EECP treatment regimens for 12 months: Group 1 (n=40): course of 35 hour-long procedures; Group 2 (n=40): course of 35 hourlong procedures every 6 months; Group 3 (n=30): course of 20 hour-long procedures then constantly 1 hour per week; Group 4 (n=30): constantly 2 hours per week; Group 5 (n=30): course of 20 hour-long procedures then constantly 2 hours per week; Group 0 (placebo ; n=40): course of 35 hour-long procedures with compression pressure 80 mm Hg. All patients at baseline and after 12 months were assessed for clinical status, quality of life (MLHFQ, SF-36), NT-proBNP levels, LVEF, as well as exercise tolerance (6-minute walk test; 6MWT) initially, after 3, 6, 9 and 12 months. Correlation analysis and risk assessment of adverse events (combined endpoint — combination of cases of adverse cardiovascular events, deaths, hospitalizations for CHF, new-onset of atrial fibrillation, diabetes, decreased renal function) was performed.Results. Treatment effectiveness had positive correlation with EECP duration (r(S)=0,670; p20% after 12 months was 7,7%, 72,5%, 97,5%, 76,7%, 90%, 100%, respectively. Cumulative event-free survival was highest in groups 5, 4, and 2 (0,97, 0,93, and 0,86, respectively), and the risk of developing combined endpoint in these groups was minimal (0,035, 0,075, and 0,150, respectively).Conclusion. The effect of EECP treatment in patients with coronary artery disease complicated by CHF depended on the EECP hours and regimen. Alternative EECP regimens (with more treatments spread evenly over the year) in addition to optimal medical therapy may improve the management of these patients.

This study used the descriptive-correlational research method to determine the medication adherence of school personnel of select public schools in Tigaon, Camarines Sur. The respondents include 213 school personnel from public secondary schools of Tigaon, Camarines Sur. The data collected were classified and tabulated systematically and statistically treated using various statistical tools. The study concluded that most of the school personnel who participated in this study were 46 years old and above. The majority were female college graduates with a gross income of 22,000 to 44,000 pesos, assigned as classroom teachers, with no known illness or comorbidities, and had outpatient consultation more than 12 months ago; majority of the respondents were adherent to their medications; socio-economic factors, healthcare team and system-related factors, therapy-related factors, and patient-related factors are significant barriers to medication adherence; and there is significant relationship between medication adherence and sex, educational level, gross income per month, illness or comorbidities, and date of last outpatient consultation. Primary actions include strengthening health education that fosters a positive attitude towards medication adherence, additional resources for medicine supplies in schools and training for healthcare workers, improving the implementation of Gulayan sa Paaralan, and exploring options to simplify treatment regimens and affordable medications. With these, the researcher proposed measures and recommendations that school administrators and public school nurses can adopt to improve the health and safety of school personnel.

Background: The optimal systemic treatment for pulmonary large-cell neuroendocrine carcinoma (LCNEC) remains controversial, and recent advances in LCNEC molecular subtype classification have provided potential strategies for assisting in treatment decisions. Our study aimed to investigate the impact of treatment regimens, molecular subtypes and their concordance on clinical outcomes of patients diagnosed with LCNEC. Patients and Methods: All patients diagnosed with advanced pulmonary LCNEC in Peking Union Medical College Hospital (PUMCH) between January 2000 and October 2021 were enrolled in this retrospective study. The tumor samples were collected and sequenced using a tumor-specific gene panel, while clinical information was retrieved from the medical records system. The survival and therapeutic response were analyzed and compared between different subgroups classified by treatment regimen (SCLC or NSCLC-based), molecular subtype (type I or II) or the combination. Results: In univariate subgroup analysis categorized only by treatment regimen or molecular subtype, there were no differences identified in DCR, ORR, PFS, or OS. Nevertheless, the group with consistent treatment regimen and molecular subtype exhibited significantly longer OS than that of the inconsistent group (median OS 37.7 vs. 8.3months; p=0.046). Particularly, the OS of patients with type II LCNEC treated with SCLC-based regimen was significantly prolonged than that of others (median 37.7 vs. 10.5months; p=0.039). Conclusions: Collectively, our study revealed the clinical outcomes of different treatment regimens for LCNEC patients highly depend on their molecular subtypes, highlighting the need for sequencing-guided therapy. [ABSTRACT FROM AUTHOR]

To examine the effect of preoperative chemoradiotherapy on the treatment outcome of patients with locally advanced oral squamous cell carcinoma. Data from 196 patients with locally advanced oral squamous cell carcinoma who underwent radical surgery with preoperative chemoradiotherapy were retrospectively reviewed. The overall, disease-specific, and relapse-free survival rates were calculated. Patient characteristics and the clinical and histopathological effects of combined chemotherapy and preoperative chemoradiotherapy were evaluated for their association with overall, disease-specific, and relapse-free survival using univariate and multivariate analyses. The overall, disease-specific, and relapse-free survival rates of all cases were 75.2%, 81.0%, and 80.0%, respectively. In univariate and multivariate analyses, histopathological treatment effect was determined as an influential factor for treatment outcome. In the multivariate analysis, N classification was also identified as an independent factor for disease-specific and relapse-free survival. The choice of chemotherapy and route of administration of anticancer agents combined with radiotherapy did not affect the treatment outcome. Preoperative chemoradiotherapy had good survival and locoregional control rates in patients with locally advanced oral squamous cell carcinoma. N classification affected primary disease control, and the histopathological effect of preoperative chemoradiotherapy influenced treatment outcomes. [ABSTRACT FROM AUTHOR]

Abstract Background Prophylaxis therapy for children with moderate and severe hemophilia A (HA) is the optimal treatment regimen. The real-world treatment regimens, patient-reported outcomes, and health-related quality of life (HRQoL) in children with moderate and severe HA in China are less known. Objective This study aimed to describe real-world treatment regimens and evaluate the association of treatment regimens with comprehensive patient-reported outcomes including bleeds, chronic pain, target joints, disability, and HRQoL in children under 18 years old with HA in China. Methods Real-world data of a nationwide online cross-sectional survey in 2021 and patients’ coagulation factor utilization data from self-management records from 2020 to 2021 were merged. 373 eligible children were included and categorized by treatment regimens according to the Chinese guideline: on-demand, short-term prophylaxis, and long-term prophylaxis treatment. Results Currently, in China, 4.8% of children with HA are receiving full-dose long-term prophylaxis treatment. Prophylaxis treatment was a significant positive predictor of better patient-reported outcomes and HRQoL. For children with prophylaxis treatment, there were significantly fewer annual bleeds (p

Abstract Background and Aim Helicobacter pylori (HP) infection remains a significant global public health problem. This study aimed to study the prevalence of HP infection and treatment outcomes in Thailand. Methods We retrospectively reviewed the results of the urea breath test (UBT) performed at the King Chulalongkorn Memorial Hospital between 2018 and 2021. The prevalence of HP infection was evaluated in dyspeptic patients undergoing UBT screening. In patients with known HP infection, the treatment regimen and the success rate in each patient were recorded. Results One‐thousand nine‐hundred and two patients were included in this study. The prevalence of HP infection in dyspeptic patients was 20.77% (UBT was positive in 65 out of 313 patients). Of the 1589 patients who received the first treatment regimen, 1352 (85.08%) had a negative UBT result. Patients who failed in each treatment regimen were treated with subsequent regimens. The overall success rates for the second, third, and fourth regimens were 69.87% (109 of 156 patients), 53.85% (14 of 26 patients), and 50% (3 of 6 patients), respectively. Univariate logistic regression analysis found that using lansoprazole was associated with failure of treatment with OR = 2.11 (95% CI: 1.14–3.92, P = 0.018). Conclusion Current primary HP treatment regimens have an eradication rate of >80%. Even though the previous regimens failed, without available antibiotic sensitivity results, the subsequent regimens were successful by at least 50%. In cases of multiple‐treatment failure and where antibiotic sensitivity tests were unavailable, continuing to change regimens could provide satisfactory results.

We estimated direct costs of a 4-month or 6-month regimen for drug-susceptible pulmonary tuberculosis treatment in the United States. Costs were $23,000 per person treated. Actual treatment costs will vary depending on examination and medication charges, as well as expenses associated with directly observed therapy.

Colorectal cancer has been around for a long time, but is still a challenge nonetheless. However, the heterogeneity of the disease opens new potential therapeutic doors. BRAF-mutated advanced colorectal cancer is a demanding entity that does not respond to standard chemotherapy regimens (FOLFOX, capecitabine) and the presence of the mutation significantly weakens the prognosis, but the rise of immunotherapy could reverse the trend. Indeed, pembrolizumab and nivolumab have boasted promising outcomes and increased survival rates among this subset of patients. This article is a collection of these results which could potentially bring immunotherapy to the front line. Colorectal cancer is still a challenge. However, the heterogeneity of the disease opens new therapeutic doors. BRAF-mutated advanced colorectal cancer is a demanding entity that does not respond to standard chemotherapy, but the rise of immunotherapy could reverse the trend. [ABSTRACT FROM AUTHOR]

Background: Prophylaxis therapy for children with moderate and severe hemophilia A (HA) is the optimal treatment regimen. The real-world treatment regimens, patient-reported outcomes, and health-related quality of life (HRQoL) in children with moderate and severe HA in China are less known. Objective: This study aimed to describe real-world treatment regimens and evaluate the association of treatment regimens with comprehensive patient-reported outcomes including bleeds, chronic pain, target joints, disability, and HRQoL in children under 18 years old with HA in China. Methods: Real-world data of a nationwide online cross-sectional survey in 2021 and patients' coagulation factor utilization data from self-management records from 2020 to 2021 were merged. 373 eligible children were included and categorized by treatment regimens according to the Chinese guideline: on-demand, short-term prophylaxis, and long-term prophylaxis treatment. Results: Currently, in China, 4.8% of children with HA are receiving full-dose long-term prophylaxis treatment. Prophylaxis treatment was a significant positive predictor of better patient-reported outcomes and HRQoL. For children with prophylaxis treatment, there were significantly fewer annual bleeds (p < 0.001), lower frequency of chronic pain(p < 0.001), and higher health utility scores(p < 0.01) and EQ-VAS scores(p < 0.05) than children with on-demand treatment. Conclusion: Accessible long-term prophylaxis treatment should be promoted for children with moderate and severe HA in China and regular monitoring of their outcomes and HRQoL should be carried out. [ABSTRACT FROM AUTHOR]

Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July 2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)% respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases.

OBJECTIVE: The main goal of this research study was to analyze the profile and prevalence of type 2 diabetic patients admitted to the MTI Khyber Teaching Hospital, Peshawar. METHODOLOGY: A hospital-based point prevalence cross-sectional descriptive study was carried out as a pilot project in November 2022 at MTI Khyber Teaching Hospital, Peshawar, Pakistan. Patients satisfying the inclusion and exclusion criteria enrolled in the study, and a non-probability consecutive sampling technique was used. RESULTS: A total of 850 patients were admitted during the study period; out of them, 24.7% had type II diabetes mellitus (T2DM). The mean length of hospital stay was significantly high among T2DM patients (p <0.01). Moreover, there were statistically significant differences X2(2) = 94.67, p <0.01, in the mode of admission among the T2DM patients, with fewer cases shifted from other units compared to ER and OPD. The antidiabetic regimen prescribed during the hospitalization included an oral antidiabetic regimen (36.9%), oral plus twice-daily insulin regimen (19.63%), and basal-bolus insulin (15.07%). CCU and ophthalmology ward had the highest proportion of admissions of T2DM patients (40% each). Patients were admitted for various indications; 11.0% were admitted due to diabetic foot ulcer, 9.5% for elective surgery, 9.55% had acute coronary syndrome (ACS), and 9.0% had diabetic kidney disease. CONCLUSION: Patients admitted exhibited a high prevalence of T2DM. We highlighted some of the substantial characteristics of these patients attending various specialties. [ABSTRACT FROM AUTHOR]

Copyright of Zdravotnícke Študie is the property of Catholic University in Ruzomberok and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background: Patients with first-line drug resistance (DR) to rifampicin (RIF) or isoniazid (INH) as a first-line (FL) line probe assay (LPA) were subjected to genotypic DST using second-line (SL) LPA to identify SL-DR (including pre-XDR) under the National TB Elimination Program (NTEP), India. SL-DR patients were initiated on different DR-TB treatment regimens and monitored for their outcomes. The objective of this retrospective analysis was to understand the mutation profile and treatment outcomes of SL-DR patients. Materials and Methods: A retrospective analysis of mutation profile, treatment regimen, and treatment outcome was performed for SL-DR patients who were tested at ICMR-NIRT, Supra-National Reference Laboratory, Chennai between the years 2018 and 2020. All information, including patient demographics and treatment outcomes, was extracted from the NTEP Ni-kshay database. Results: Between 2018 and 2020, 217 patients out of 2557 samples tested were identified with SL-DR by SL-LPA. Among them, 158/217 were FQ-resistant, 34/217 were SLID-resistant, and 25/217 were resistant to both. D94G (Mut3C) of gyrA and a1401g of rrs were the most predominant mutations in the FQ and SLID resistance types, respectively. Favorable (cured and treatment complete) and unfavorable outcomes (died, lost to follow up, treatment failed, and treatment regimen changed) were recorded in a total of 82/217 and 68/217 patients in the NTEP Ni-kshay database. Conclusions: As per the testing algorithm, SL- LPA is used for genotypic DST following identification of first-line resistance, for early detection of SL-DR in India. The fluoroquinolone resistance pattern seen in this study population corelates with the global trend. Early detection of fluoroquinolone resistance and monitoring of treatment outcome can help achieve better patient management. [ABSTRACT FROM AUTHOR]

Background and Aim: Helicobacter pylori (HP) infection remains a significant global public health problem. This study aimed to study the prevalence of HP infection and treatment outcomes in Thailand. Methods: We retrospectively reviewed the results of the urea breath test (UBT) performed at the King Chulalongkorn Memorial Hospital between 2018 and 2021. The prevalence of HP infection was evaluated in dyspeptic patients undergoing UBT screening. In patients with known HP infection, the treatment regimen and the success rate in each patient were recorded. Results: One‐thousand nine‐hundred and two patients were included in this study. The prevalence of HP infection in dyspeptic patients was 20.77% (UBT was positive in 65 out of 313 patients). Of the 1589 patients who received the first treatment regimen, 1352 (85.08%) had a negative UBT result. Patients who failed in each treatment regimen were treated with subsequent regimens. The overall success rates for the second, third, and fourth regimens were 69.87% (109 of 156 patients), 53.85% (14 of 26 patients), and 50% (3 of 6 patients), respectively. Univariate logistic regression analysis found that using lansoprazole was associated with failure of treatment with OR = 2.11 (95% CI: 1.14–3.92, P = 0.018). Conclusion: Current primary HP treatment regimens have an eradication rate of >80%. Even though the previous regimens failed, without available antibiotic sensitivity results, the subsequent regimens were successful by at least 50%. In cases of multiple‐treatment failure and where antibiotic sensitivity tests were unavailable, continuing to change regimens could provide satisfactory results. [ABSTRACT FROM AUTHOR]

Abstract Background The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late-onset rheumatoid arthritis (LORA) is traditionally defined as the onset of RA after the age of 60 years. Compared to younger-onset rheumatoid arthritis (YORA) which occurs before the age of 60 years, LORA has unique characteristics and disease manifestations. To date, few reports have addressed LORA and the prognosis of LORA patients remains unclear. We compared the clinical characteristics, time to remission and treatment regimen at remission between LORA and YORA patients. Methods This prospective cohort study used a registry database in Ontario, Canada from 2008 to 2020. Patients were included if they had active rheumatoid arthritis (RA) disease (≥1 swollen joint) and were enrolled within 1 year of diagnosis. LORA was defined as a diagnosis of RA in persons 60 years and older and YORA as a diagnosis of RA in persons under the age of 60. Remission was defined by Disease Activity Score 28 (DAS28) ≤2.6. A multivariable Cox proportional hazards model was used to estimate time to remission. Results The study included 354 LORA patients and 518 YORA patients. The mean (standard deviation) baseline DAS28 score was 5.0 (1.3) and 4.8 (1.2) in LORA and YORA patients, respectively (p=0.0946). Compared to YORA patients, the hazard ratio for remission in LORA patients was 1.10 (95% confidence interval 0.90 to 1.34 p=0.36) after adjusting for other prognostic factors. For patients who reached remission, LORA patients were less likely to be on a biologic or Janus kinase (JAK) inhibitor (16% vs. 27%) and more likely to be on a single conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) (34% vs. 27%) than YORA patients (p=0.0039). Conclusion LORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without a biologic or JAK inhibitor.

Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real‐world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first‐line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced‐stage disease, and 48% of patients with the early‐stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥60 years of age with advanced‐stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early‐stage disease, and 88% in advanced‐stage disease. Early progression‐free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies. [ABSTRACT FROM AUTHOR]

Preplanned dose titrations are sometimes used in clinical trials to improve patient tolerability to treatment. Such titrations often start from a low dose and gradually increase to the targeted dose, and therefore, the low-dose and high-dose arms may share the same dose for a certain period of time. Traditionally, the analysis has been performed according to the treatment arm, ignoring the fact that there are overlapping initial doses between arms. This article describes an alternative method of analysis that exploits the design feature on titrations to produce a more efficient estimation for the mean response over time for each treatment regimen as well as the comparison between treatment regimens for continuous, time-to-event, binary, and count variables. For continuous and count data, we used the (generalized) linear mixed model framework to construct the new estimators; for time-to-event data, we developed a novel logrank test; and for the binary variable, we derived the point and variance estimators based on the events that occurred in each study period. Simulation studies and the application to a real clinical dataset demonstrate the newly proposed approach is advantageous over the traditional approach. [ABSTRACT FROM AUTHOR]

A personalized vitamin D3 loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D3 daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D > 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (n = 5 in verum and n = 1 in the placebo group; p = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D3 daily sustained the achieved levels. [ABSTRACT FROM AUTHOR]

Abstract Background To verify the efficacy and safety of an inexpensive standardized regimen for multidrug-resistant tuberculosis (MDR-TB) with low resistance to isoniazid (INH), a multicenter prospective study was conducted in eastern China. Methods Patients diagnosed as MDR-TB with low concentration INH resistance and rifampicin resistance, second-line/injectable agents sensitive were prospectively enrolled, given the regimen of Amikacin (Ak)–Fluoroquinolones (FQs)–Cycloserine (Cs)–Protionamide (Pto)–PasiniaZid (Pa)–Pyrazinamide (Z) for 6 months followed by 12 months of FQs–Cs–Pto–Pa–Z, and then followed up for treatment outcomes and adverse events (AEs). Results A total of 114 patients were enrolled into the study. The overall favorable treatment rate was 79.8% (91/114). Among 91 cases with favorable treatment, 75.4% (86/114) were cured and 4.4% (5/114) were completed treatment. Regarding to unfavorable outcomes, among 23 cases, 8.8% (10/114) had failures, 8.8% (10/114) losing follow up, 0.9% (1/114) had treatment terminated due to intolerance to drugs and 1.8% (2/114) died. Treatment favorable rate was significantly higher in newly treated MDR-TB (91.7%, 33/36) than that in retreated MDR-TB (74.4%, 58/78, p 0.03). The investigators recorded 42 AEs occurrences in 30 of 114 patients (26.3%). Clinicians rated most AEs as mild or moderate (95.24%, 40/42). Conclusions The regimen was proved to be effective, safe and inexpensive. It is suitable for specific drug resistant population, especially for newly-treated patients, which could be expected to be developed into a short-course regimen. Clinical trials registration China Clinical Trial Registry ChiCTR-OPC-16009380

The peculiarities of microwave radiation of materials for physiotherapy are considered in the work. The presence and changes of radiation levels in the mm range during the technological cycle of the procedure are considered on the example of ozokerite-paraffin applications. It is shown that an important component of physiotherapeutic procedures is microwave electromagnetic radiation generated by a heated ozokerite-paraffin mixture. Using the experimental setup developed by the authors, studies of the emissivity of ozokerite, paraffin and their mixtures in the microwave range. The radiation power of materials is compared with the level of radiation of the human body. It is shown that during the procedure, the change in temperature leads to the appearance of positive and negative fluxes of microwave radiation, which have different effects on the human body. The obtained results of experimental researches allowed estimating the interaction of electromagnetic radiation of ozokerite-paraffin mixtures with the person's own electromagnetic radiation and taking a more balanced approach to the choice of treatment regimens.

Purpose: Age-related macular degeneration (AMD) is one of the main causes of blindness and visual impairment worldwide. As achieving a dry macula is one of the main objectives in AMD management, the purpose of this work was to reach a consensus on the relevance of retinal fluid in function, disease activity control and treatment patterns. Methods: Forty-seven Portuguese ophthalmologists specialized in AMD participated in a DELPHI panel. Two rounds of presential meetings were conducted and a cut-off of 80% or more of votes was defined to consider answers consensual. Results: Consensus was reached for 11 out of 18 questions. These questions focused on the impact of anatomical results on visual acuity, standards exams and parameters to assess disease activity, frequency and factors which influence disease activity assessment, criteria to use non-fixed treatment regimens, usefulness of individualized regimens and conditions for treatment interruption. No consensus was obtained for relevance of the different fluid types in AMD prognosis, frequency of fluid presence assessment, factors commonly associated with progression to geographic atrophy, ideal conditions for a fixed treatment regimen, date of first disease activity assessment and parameters to monitor disease activity. Conclusions: Consensus was achieved for over half of the questions assessed through this Delphi study. The questions for which no consensus was reached concerned either subjects that need further investigation or monitoring times which are influenced by resource availability. Raising awareness for these issues will allow the improvement of AMD management and treatment. [ABSTRACT FROM AUTHOR]

BackgroundMaintenance hemodialysis is typically prescribed thrice weekly irrespective of a patient's residual kidney function (RKF). We hypothesized that a less frequent schedule at hemodialysis therapy initiation is associated with greater preservation of RKF without compromising survival among patients with substantial RKF.Study designA longitudinal cohort.Setting & participants23,645 patients who initiated maintenance hemodialysis therapy in a large dialysis organization in the United States (January 2007 to December 2010), had available RKF data during the first 91 days (or quarter) of dialysis, and survived the first year.PredictorIncremental (routine twice weekly for >6 continuous weeks during the first 91 days upon transition to dialysis) versus conventional (thrice weekly) hemodialysis regimens during the same time.OutcomesChanges in renal urea clearance and urine volume during 1 year after the first quarter and survival after the first year.ResultsAmong 23,645 included patients, 51% had substantial renal urea clearance (≥3.0mL/min/1.73m(2)) at baseline. Compared with 8,068 patients with conventional hemodialysis regimens matched based on baseline renal urea clearance, urine volume, age, sex, diabetes, and central venous catheter use, 351 patients with incremental regimens exhibited 16% (95% CI, 5%-28%) and 15% (95% CI, 2%-30%) more preserved renal urea clearance and urine volume at the second quarter, respectively, which persisted across the following quarters. Incremental regimens showed higher mortality risk in patients with inadequate baseline renal urea clearance (≤3.0mL/min/1.73m(2); HR, 1.61; 95% CI, 1.07-2.44), but not in those with higher baseline renal urea clearance (HR, 0.99; 95% CI, 0.76-1.28). Results were similar in a subgroup defined by baseline urine volume of 600mL/d.LimitationsPotential selection bias and wide CIs.ConclusionsAmong incident hemodialysis patients with substantial RKF, incremental hemodialysis may be a safe treatment regimen and is associated with greater preservation of RKF, whereas higher mortality is observed after the first year of dialysis in those with the lowest RKF. Clinical trials are needed to examine the safety and effectiveness of twice-weekly hemodialysis.

Abstract Background Globally, malaria is still a major public health challenge. Drug-based treatment is the primary intervention in malaria control and elimination. However, optimal use of mass or targeted treatments remains unclear. A variety of radical, preventive and presumptive treatment regimens have been administrated in China and a systematic review was conducted to evaluate effectiveness, and discuss experiences, limitations, and lessons learnt in relation to the use of these regimens. Methods The search for information includes both paper documents, such as books, malaria control annals and guidelines for malaria prevention and treatment, as well as three computer-based databases in Chinese (CNKI, WanFangdata and Xueshu.baidu) and two databases in English (PubMed and Google Scholar), to identify original articles and reports associated with drug administration for malaria in China. Results Starting from hyperendemicity to elimination of malaria in China, a large number of radical, preventive and presumptive treatment regimens had been tried. Those effective regimens were scaled up for malaria control and elimination programmes in China. Between 1949 and 1959, presumptive treatment with available anti-malarial drugs was given to people with enlarged spleens and those who had symptoms suggestive of malaria within the last 6 months. Between 1960 and 1999, mass drug administration (MDA) was given for preventive and radical treatment. Between 2000 and 2009, the approach was more targeted, and drugs were administed only to prevent malaria infection in those at high risk of exposure and those who needed radical treatment for suspected malaria. Presumptive therapy was only given to febrile patients. From 2010, the malaria programme changed into elimination phase, radical treatment changed to target individuals with confirmed either Plasmodium vivax or Plasmodium ovale within the last year. Preventive treatment was given to those who will travel to other endemic countries. Presumptive treatment was normally not given during this elimination phase. All cases of suspected were confirmed by either microscopy or rapid diagnosis tests for malaria antigens before drugs were administered. The engagement of the broader community ensured high coverage of these drug-based interventions, and the directly-observed therapy improved patient safety during drug administration. Conclusion A large number of radical, preventive and presumptive treatment regimens for malaria had been tried in China with reported success, but the impact of drug-based interventions has been difficult to quantify because they are just a part of an integrated malaria control strategy. The historical experiences of China suggest that intervention trials should be done by the local health facilities with community involvement, and a local decision is made according to their own trial results.

Drugs for alopecia areata (AA) can induce hair regrowth, but do not change the disease course. Dual properties of cyclosporine A (CsA) as hypetrichotic and immunosuppressive agent have encouraged use in AA. We aimed to determine the most meaningful efficacy of CsA and reveal features helping enhance its efficacy and reduce relapses. Efficacy of CsA and predictive factors were investigated. Cochrane, MEDLINE, Pubmed and Embase databases were searched. 2,189 papers were retrieved. Based on 344 patients, mean proportion of responders was 73%. CsA monotherapy showed proportion of hair regrowth of 66%, whereas CsA combined with systemic corticosteroids yielded 78%. Overall efficacy in studies with duration of CsA treatment <6 months was: 74% (53–88%), while in those with duration ≥6 months was: 73% (47–89%). Recurrence with CsA monotherapy was 55% (6–96%) whereas when CsA was combined with systemic corticosteroids it was 28% (6–72%). CsA confers a favorable therapeutic effect and concomitant use of steroids slightly enhances efficacy, but it dramatically decreases relapses. Longer treatments seem to lead to less relapse likelihood, but daily dose does not influence recurrence. Optimal CsA dosage is 5 mg/kg/day in single therapy regimen, whereas it is 3 mg/kg/day in the steroid-associated regimen. What is already known about this subject? Most treatments for alopecia areata have not been critically evaluated. Current outcomes about the efficacy and relapse rate of cyclosporine A (CsA) are inconsistent and predictive factors about the clinical response are lacking. What this study adds? CsA confers a favorable therapeutic hair regrowth. Longer treatment seems to lead to less likelihood of relapse of AA, but the daily dose does not exert any effect on the recurrence of the disease. The concomitant use of corticosteroids broadly decreases relapses, and it also enhances efficacy. Impact on clinical practice The combination with corticosteroids is the most predictive feature to prevent relapse of AA, followed by the duration of CsA therapy. The daily dose of CsA is the feature with the least or null impact on the clinical course of AA. [ABSTRACT FROM AUTHOR]

Michelle McNamara,1 Diane M Turner-Bowker,2 Hal Westhead,3 Andrew Yaworsky,2 Andrew Palladino,4 Hillary Gross,1 Andy Pleil,5 Jane Loftus6 1Adelphi Research, Doylestown, PA, USA; 2Adelphi Values, Boston, MA, USA; 3Adelphi Research, Manchester, UK; 4Pfizer, Inc., Collegeville, PA, USA; 5Endpoints and Evidence, LLC, Surf City, NC, USA; 6Pfizer Ltd., Tadworth, UKCorrespondence: Jane LoftusPfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS, UKTel +44 1737 330032Email Jane.Loftus@Pfizer.comIntroduction: The daily injection burden of recombinant human growth hormone (r-hGH) replacement therapy to treat growth hormone deficiency (GHD) may reduce compliance and limit treatment benefit. Research is needed to evaluate patient preferences for GHD injection regimen and device features.Objective: Quantitatively evaluate factors driving preferences for r-hGH injection regimen and device features among pediatric (3– 17 years, and caregivers) and adult (≥ 25 years) patients with GHD using a discrete choice experiment (DCE) approach.Methods: The DCE was part of a broader, cross-sectional observational field study to develop clinical outcome assessments (COAs) that assess the experience of patients taking r-hGH injections. Following ethics approval, discrete choice data were collected through an online questionnaire from consented participants recruited from eight sites in the United States. Participants were presented with 20 choice tasks, each comprising different combinations of two profiles. Participants were then shown the same set of three hypothetical device and injection profiles (ie, storage, preparation, injection type device, maintenance, dose setting, injection schedule) and asked whether they would choose each profile over their current device and schedule. Choice-based conjoint analyses were used to estimate the marginal utilities and values for treatment attributes. Subject preferences were estimated at individual and aggregate levels.Results: Two hundred and twenty-four participants completed the DCE (n=75 adults, n=79 adolescent/caregiver dyads, n=70 child/caregiver dyads). Injection schedule was the strongest predictor of choice for the total sample and each patient group. Less frequent injection schedules were more likely to be chosen by participants. A “ready to use” injection was preferred, with no preference for auto-injector versus needle-free device. Most participants would choose the hypothetical injection devices and less frequent dosing over their current daily administered device schedule.Conclusion: Patients prefer a less frequent injection regimen for treating GHD. Addressing patient preferences may improve compliance, adherence, and ultimately, clinical outcomes.Keywords: discrete choice experiment, DCE, conjoint analysis, treatment regimen, attributes, children, adults

BACKGROUND AND OBJECTIVE: Cardiovascular disease is the leading cause of a large percentage of deaths worldwide. With the improvement in the survival of coronary artery disease patients in recent decades, continuous self-care programs (based on education and prevention) are increasingly recommended. The aim of this study was to evaluate the effect of continuous care model on quality of life, self-efficacy and adherence to the treatment regimen of patients undergoing coronary artery bypass graft. METHODS: This quasi-experimental study was performed with a single group before and after the intervention among 85 patients undergoing coronary artery bypass grafting in Tehran Social Security hospitals in 2016. Data were collected based on demographic questionnaires, McNew quality of life (lowest score 27 and highest score 189), general self-efficacy (lowest score 10 and highest score 40), and researcher-made regimen questionnaire (3 areas of diet, medication, and physical activity), (score of each domain 0-100%, undesirable adherence: less than 50% of the total score, desirable adherence: more than 75% of the total score). The intervention was based on the continuous care model (orientation, sensitization, control, evaluation). Training sessions were held for 4 weeks (stages 1 and 2) while control and evaluation were performed during 8 weeks after that. Questionnaires were completed and analyzed by patients before and 3 months after the intervention. FINDINGS: The results showed that the scores of quality of life, self-efficacy and treatment regimen of patients before the intervention were 72.08±3.55, 25.08±2.48 and 180.18±9.61, respectively, and after the intervention were 85.13±0.63, 38.76±1.11, and 287.94±2.36, respectively. There was a statistically significant difference between the mean score of self-efficacy, quality of life and treatment regimen before and after the intervention (p

Introduction: Adherence to the treatment regimen is among the key principles in chronic diseases, like thalassemia. The difficult treatment of these patients and the significant biopsychosocial changes that occur during adolescence may lead to numerous psychosocial changes. Such issuesmay affect their adherence to the treatment regimen. Objective: The current study aimedto determine the relationship between psychosocial status and adherence to the treatment regimen in adolescents with thalassemia referring to hospitals in Rasht City, Iran. Materials and Methods: Cross-sectional study was conducted on 66 adolescents with thalassemia. The study samples included patients aged 11-21 years, referring to two hospitals in Rasht City, Iran, in 2017. They were selected using the census methods. Data collection tools included a demographic form and Pediatric Symptom Checklist-Youth Report (PSC-Y). The compliance rate was measured by evaluating their adherence to follow-up visits, average results of the last three ferritin tests, and iron chelator use. The collected data were analyzed using descriptive statistics and the Chi-squared test, Fisher’s exact test, and regression analysis. Results: Fifty percent of patients reported psychosocial problems and most of them had good adherence to follow-up visits (74.2%); however, their adherence to ferritin tests (47%) and iron chelator use (45.5%) was poor. Regression analysis results suggested that the effect of psychosocial status on adherence to follow-up visits (P

Background: Patients with first-line drug resistance (DR) to rifampicin (RIF) or isoniazid (INH) as a first-line (FL) line probe assay (LPA) were subjected to genotypic DST using second-line (SL) LPA to identify SL-DR (including pre-XDR) under the National TB Elimination Program (NTEP), India. SL-DR patients were initiated on different DR-TB treatment regimens and monitored for their outcomes. The objective of this retrospective analysis was to understand the mutation profile and treatment outcomes of SL-DR patients. Materials and Methods: A retrospective analysis of mutation profile, treatment regimen, and treatment outcome was performed for SL-DR patients who were tested at ICMR-NIRT, Supra-National Reference Laboratory, Chennai between the years 2018 and 2020. All information, including patient demographics and treatment outcomes, was extracted from the NTEP Ni-kshay database. Results: Between 2018 and 2020, 217 patients out of 2557 samples tested were identified with SL-DR by SL-LPA. Among them, 158/217 were FQ-resistant, 34/217 were SLID-resistant, and 25/217 were resistant to both. D94G (Mut3C) of gyrA and a1401g of rrs were the most predominant mutations in the FQ and SLID resistance types, respectively. Favorable (cured and treatment complete) and unfavorable outcomes (died, lost to follow up, treatment failed, and treatment regimen changed) were recorded in a total of 82/217 and 68/217 patients in the NTEP Ni-kshay database. Conclusions: As per the testing algorithm, SL- LPA is used for genotypic DST following identification of first-line resistance, for early detection of SL-DR in India. The fluoroquinolone resistance pattern seen in this study population corelates with the global trend. Early detection of fluoroquinolone resistance and monitoring of treatment outcome can help achieve better patient management.

Background: This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved., Methods: We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL., Results: The most used regimen (46.8%) for GBM in patients aged ≤74 years was 'Surgery + radiotherapy concomitant with temozolomide'. This regimen's total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, 'Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy' was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month)., Conclusions: Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors., (© The Author(s) 2024. Published by Oxford University Press.)

Introduction: Cardiovascular diseases (CVDs) such as hypertension, ischemic heart disease, and stroke are highly prevalent and have a significant impact on quality of life and the healthcare economy. This study aimed to evaluate adherence to medication regimens in CVD patients., Materials and Methods: A cross-sectional descriptive study of 203 patients was conducted using a semi-structured questionnaire which included an eight item Morisky Medication Adherence Scale (MMAS-8) to assess medication compliance., Results: The survey included 203 patients, 164 (81%) males and 39 (19%) females. Overall, 156 (76.8%) had medical insurance, while only 47 (23.2%) were not medically insured. In total, 161 patients (79.3%) adhered to the medical regimen., Conclusion: Most participants adhered to their treatment regimen in the present study. However, inadequate knowledge regarding side effects and abrupt discontinuation of medications without physician consultation was reported to a high degree. These findings highlight the areas for improvement in healthcare to improve medication adherence rates., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee of Vydehi Institute of Medical Sciences and Research Centre issued approval #VIEC/2017/APP/068. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Agarwal et al.)

The present study compared the efficacy of amitraz, doramectin, imidacloprid + moxidectin, test product (Green clean), and its combinations in the clinical management of canine generalized demodicosis. A total of 48 positive cases of generalized demodicosis were selected for the therapeutic trial. The affected dogs were divided into 6 groups, viz., A, B, C, D, E, and F; each group comprised 8 dogs. Six healthy dogs negative for demodectic mites were also used as control (group G) for comparison. The response to treatment was assessed by conducting a clinical examination and parasitological examination of cases at weekly intervals included in the therapeutic trial till clinical recovery (4-7 weeks) or treatment failure. Treatment regimens comprising of a combination of systemic miticidal drugs (doramectin @ 600 µg/kg b. wt. s/c weekly) and a topical miticidal compound (amitraz @ 500 ppm spray weekly or test product 5% spray twice daily) with supportive therapy were more efficacious in resolving the lesions and eliminating the mites than the treatment regimens having single drug (doramectin/amitraz/test product). The combination therapy, along with supportive therapy with benzyl peroxide shampoo, produced appreciable therapeutic results. There was no significant difference between different treatment groups, except Group D (test product), which took a long time for clinical cure. [ABSTRACT FROM AUTHOR]

As a data-driven healthcare service, automatic treatment regimen design has great potential to improve healthcare efficiency and quality. However, it is a nontrivial endeavor to develop such a healthcare service due to two major challenges: 1) the treatment records are complex data objects consisting of various semantic and temporal information, and 2) the treatment outcome usually depends on a large number of internal and external factors. Because of these difficulties, automatic treatment regimen design is still an open research problem nowadays. To fill this research gap, this paper first formulates a treatment sequence as temporal sets, then provides a novel Extended Jaccard Similarity (EJS) measure to quantify the similarities between treatment sequences. We show that the proposed EJS is a general and effective measure to capture the similarity between two complex temporal sets. Further, we develop an efficient clustering algorithm which can achieve reasonable clustering results with only a portion of the pairwise similarities between treatment sequences and then extract a semantic prototype of the treatment regimen from each cluster of treatment sequences. Finally, we adopt a matrix factorization framework to predict the treatment outcomes by integrating multiple internal and external factors. We conduct comprehensive experiments on Electronic Medical Records (EMRs) of more than 28,000 patients from 14 hospitals. The results demonstrate the effectiveness of our approach and its superiority over the state-of-the-art ones. [ABSTRACT FROM AUTHOR]

AIM: To compare two different anti-vascular endothelial growth factor (anti-VEGF) treatment regimens’-a priori pro re nata (PRN) and PRN regimen following the loading phase-anatomical and functional results in neovascular age-related macular degeneration (nAMD) patients. METHODS: Totally 544 nAMD patients followed and treated with aflibercept (n=135) and ranibizumab (n=409) at 9 different centers between 2013 and 2015 were enrolled into this retrospective multicenter study. Patients with initial best corrected visual acuity (BCVA) interval of 1.3-0.3 (logMAR) and a minimum follow-up of 12mo were included. Patients under two different regimens-a priori pro re nata (1+PRN) or 3 consecutive intravitreal injections followed by a PRN regimen (3+PRN)-were compared in BCVA at 3th, 6th and 12th months, and in central macular thickness (CMT) at 6th and 12th months. The total study group, intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) groups were evaluated separately. RESULTS: The mean CMT decreased in the 1+PRN (n=101) regimen from 407 to 358 and 340 µm and in the 3+PRN (n=443) group from 398 to 318 and finally to 310 µm at months 6 and 12, respectively. Anatomically, the CMT reduction at 6th month (48.5 vs 76.4; P